Arlington Asset Investment Corp.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. Rock Tonkel Jr., CPA
- Full Time Employees
- 9
- Sector
- Real Estate
- Industry
- REIT - Mortgage
- Address
- Potomac Tower Arlington VA United States of America 22209
- IPO Date
- Dec 23, 1997
- CIK
- 0001209028
- Website
- arlingtonasset.com
- Similar Companies
- Business
- Arlington Asset Investment Corp. is a mortgage real estate investment trust primarily engaged in investing in mortgage-related and residential real estate assets. The company’s core investment portfolio includes mortgage servicing rights (MSR) related assets, credit investments secured by residential or commercial real estate or non-agency mortgage-backed securities (MBS), single-family residential rental properties, and agency MBS guaranteed by government-sponsored enterprises such as Fannie Mae and Freddie Mac. Arlington Asset funds its investments mainly through short-term financing arrangements like repurchase agreements and employs hedging strategies to manage interest rate sensitivity related to its borrowing costs and MBS portfolio. Headquartered in McLean, Virginia, and founded in 1997, Arlington operates predominantly within the U.S. residential mortgage and real estate sectors. In recent major developments, Arlington Asset Investment Corp. announced a definitive merger agreement with Ellington Financial Inc. in May 2023. This strategic transaction, completed by the end of 2023, enhanced the combined company’s scale, liquidity, and capital market access, aligning complementary mortgage servicing rights portfolios with an expected pro forma equity capital base exceeding $1.5 billion. The merger aims to drive earnings accretion, operational efficiencies, and long-term growth by leveraging Arlington’s relatively low leverage and Ellington’s existing management platform and expertise. Additionally, Arlington has focused recently on preserving capital, managing liquidity, and capitalizing on market opportunities amid evolving conditions. It has also repurchased shares and successfully closed sales of single-family residential properties as part of its portfolio management. Arlington Asset targets institutional investors seeking long-term returns through exposure to diversified mortgage-related assets. Its business segments include mortgage servicing rights financing, credit investments, single-family rental properties, and agency MBS investments across the United States. The company elected to be taxed as a REIT in 2019, emphasizing a multi-channel investment strategy beyond its historical agency MBS focus. Through its partnership with Ellington Financial, Arlington is positioned to leverage combined operational strengths and expanded financial resources to capitalize on growing opportunities in residential real estate finance and credit markets. This comprehensive strategic repositioning and merger combine Arlington’s deep expertise in mortgage servicing rights and residential real estate investment with Ellington’s diversified financial asset platform, reflecting a significant shift to broader mortgage credit sectors and scalable growth. The company’s headquarters are located in the Washington, D.C. metropolitan area, from which it manages its diverse real estate investment trust portfolio. Overall, Arlington Asset Investment Corp. operates as a specialized mortgage REIT focused on delivering shareholder value through diversified mortgage-related investments, supported by recent transformative corporate actions including the merger with Ellington Financial Inc. and active portfolio management initiatives in U.S. residential mortgage markets.
BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025
NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025
Annovis to Attend the AAIC 2025 with Four Poster Presentations
Preferreds Weekly Review: AAIC Delists Its Bonds
Arlington Asset Investment Corp. Announces Intention to Delist Notes from the NYSE
Arlington Asset Investment Corp. Shareholders Approve Merger with Ellington Financial Inc.
Pivot Pending
Rates Down, REITs Up
Disinflation Is Back
Arlington Asset Investment Corp. Reports Third Quarter 2023 Financial Results
ARLINGTON ASSET INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arlington Asset Investment Corp. - AAIC
Big Dividend Yields Going Higher, Dumb Debt, And Snark
Arlington Asset Investment Corp: Price Hike Due To Acquisition Deal
Arlington Asset Investment Corp. Declares Third Quarter 2023 Dividends on Preferred Stock
REITs Are Historically Cheap